Tom Nolan reviews this week’s research “Small individual gain, larger population gain” sounds like the theme for a preventive medicine conference. It’s actually the headline of an editorial about a ...

For early postmenopausal women, zoledronate administered at baseline and 5 years is effective for preventing morphometric vertebral fracture.

For early postmenopausal women, zoledronate administered at baseline and five years is effective for preventing morphometric vertebral fracture, according to a study published in the Jan.

Intravenous zoledronate (Reclast) administered once every 5 years reduced the incidence of morphometric vertebral fractures in early postmenopausal women, a randomized trial showed. Over 10 years ...

Using data from 638,999 patients, a new study by a research team at the Warren Alpert Medical School found that the incidence ...

Opens in a new tab or window Intravenous zoledronate (Reclast) administered once every 5 years reduced the incidence of morphometric vertebral fractures in early postmenopausal women, a randomized ...

15, 2025 (HealthDay News) -- For early postmenopausal women, zoledronate administered at baseline and five years is effective for preventing morphometric vertebral fracture, according to a study ...

Whether infrequent zoledronate administration would prevent vertebral fractures in early postmenopausal women is unknown. We conducted a 10-year, prospective, double-blind, randomized, placebo ...

Women who went 5 years between zoledronate infusions had a 44% lower risk for morphometric vertebral fractures than women receiving placebo. More research is needed to assess the optimal dosing ...

An 81-year-old man with longstanding ankylosing spondylitis presented to the emergency department with pain in his lower back 2 days after a fall from standing height. The pain from the injury made it ...